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Following publication of this manuscript, the authors discovered some panels that had been incorrectly cropped in Figures S4H and
S5V in the Supplemental Information.
As a result of this error, the 0 hr time points of the top PARP-1 panel of Figure S4H, U266, the Tot-JNK and Tot-ERK panels of
Figure S5V, U266, and the P-p38 panel of Figure S5V, RPMI-8226, as well as the 0 hr and 0.5 hr, DTP3, time points of the P-ERK
panel of Figure S5V, RPMI-8226, were accidentally omitted from these panels. An extra time point (i.e., a 1.5 hr time point, T/I)
was also accidentally included in the P-ERK panel of this figure. Due to an analogous error, the P-JNK panel of Figure S5V,
RPMI-8226, was incorrectly aligned.
The authors also discovered an antibody that had been erroneously omitted from the Supplemental Experimental Procedures. This
antibody, anti-PARP-1 (9532S; 1:1,000), should have been included in the section ‘‘Antibodies, Reagents and Western Blots.’’
A corrected version of the Supplemental Information is now available online.Dissecting the Tumor Myeloid Compartment
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FLT3L and FLT3 were erroneously written as FTL3L and FTL3 at multiple points in the text. Only FLT3L (FMS-like tyrosine kinase
ligand) and FLT3 (FMS-like tyrosine kinase) are discussed in this paper. These errors have been corrected online.938 Cancer Cell 26, 938, December 8, 2014 ª2014 Elsevier Inc.
